Important Safety Information
Full Prescribing Information
Visit Peer2Peer Clinical Education
About
OMIDRIA
Reimbursement Guide
Review this important office guide for coding and billing assistance, including sample claim forms
We Pay the Difference Fact Sheet
Review this guide for an overview on how to complete the enrollment process for each commercially insured We Pay the Difference patient
We Pay the Difference Enrollment Form
Enroll commercially insured patients in the We Pay the Difference reimbursement program
OMIDRIAssure Patient Certification Form
Determine patient eligibility for the Equal Access patient assistance program
Letter of Medical Necessity
Use this template letter to communicate with payers; this letter can be customized to establish the medical reason that OMIDRIA was used
Reimbursement Assistance
For more information, please contact an OMIDRIA Field Reimbursement Manager.
DISCOVER RESOURCES & SUPPORT
View or download resources for you, your practice, ASC, or patients
ASC=ambulatory surgery center; HOPD=hospital outpatient department.
Indications and Usage
OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.
Important Safety Information
OMIDRIA must be added to irrigating solution prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure to phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.
The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA.
You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Indications and Usage
OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.
Important Safety Information
OMIDRIA must be added to irrigating solution prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure to phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.
The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA.
You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.